Freely Filtered does Pip/Tazo and Vanco. Toxin or pseudotoxin?

The Filtrate looks at a trial that tries to dissect the bumps in creatinine we regularly see with Pip/Tazo. Is it AKI or pseudonephrotoxicity?

Freely Filtered does ADVOR

ADVOR turns the practice of sequential nephron blockade on its head by blocking the proximal tubule before the loop of Henle. Does it work? Join The Filtrate as we dissect the latest diuretic RCT.

Freely Filtered does EMPA-Kidney

Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.

New player in resistant hypertension?

This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!

Would a new drug option for resistant hypertension get you excited? How about a superior trial design?

Time to learn about PRECISION - our twitter journal club had 720 tweets, but you can catch the highlights quickly with the regular #TenTweetNephJC thread👇 pic.twitter.com/YH1P4rCIRG

— Nephrology Journal Club (@NephJC) December 9, 2022

The PRECISION Visual Abstract

Is Aprocitentan effective in lowering BP in resistant hypertension? PRECISION trial answers it with a meticulous design. Checkout the VA by NSMC intern Sandhya Suresh which captures many elements of that meticulous design.

View fullsize

Another EMPA-Kidney Tweetorial

Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney

7 ways the EMPA-KIDNEY trial will impact clinical care in CKD

A Thread 🧵

Sources @NEJM @NephJC @DiabetesCanada @AmDiabetesAssn @goKDIGO @ESC_Journals @hswapnil @kidney_boy

— Daniel Schwartz (@drdschwartzmd) November 27, 2022

Don't Stop Me Now!

If you missed the latest NephJC discussion, at least read the highlights here.

You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.

Welcome to #TenTweetNephJC

✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/n8dcopDLPT

— Nephrology Journal Club (@NephJC) December 1, 2022

TESTING 2.0 in Kidney Medicine

The NephJC editorial in Kidney Medicine is live. Great work from Anand Chellapan and Rachael Kermond, supported by Tiffany, Jade and Swap. Read it here.

With a bonus table which already needs updating post EMPAKIDNEY!

The STOP ACEi Trial - Visual Abstract

Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD? NSMC Intern Dana Larsen explains it graphically.

View fullsize

Flozins strike again!

If you missed the biggest NephJC of the year, at least read the highlights here.

If you only read one #TenTweetNephJC this year, make it this one.

EMPA-KIDNEY is one of those landmark trials it is worth knowing inside-out, but you can still rapidly catch up on the key findings & author tweetchat secrets in the thread below👇 pic.twitter.com/VL2u8BoCLw

— Nephrology Journal Club (@NephJC) November 22, 2022

The future for refractory lupus nephritis?

Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!

Welcome to #TenTweetNephJC

✳️ 10 tweets #NephJC catch-up ✳️

Here’s a recap of our 25th Oct #NephJC discussion on ‘Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus’ - better late than never!

Check out the paper at https://t.co/HxTcVC3PtH pic.twitter.com/y7o71HUPiZ

— Nephrology Jrnl Club (@NephJC) November 18, 2022